Stay updated on Autologous TILs in Metastatic TNBC Clinical Trial

Sign up to get notified when there's something new on the Autologous TILs in Metastatic TNBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Autologous TILs in Metastatic TNBC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T23:02:04.000Z thumbnail image
  5. Check
    4 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy evaluation of autologous LN-145 therapy in patients with metastatic Triple Negative Breast Cancer (TNBC). This change reflects a shift in the objective response rate (ORR) assessment using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
    Difference
    0.1%
    Check dated 2024-06-06T14:43:59.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to provide a detailed explanation of eligibility criteria, including examples such as general health condition or prior treatments, and the requirement for written informed consent. This change likely pertains to medical and healthcare-related documentation, specifically in the context of clinical research studies.
    Difference
    40%
    Check dated 2024-05-22T21:18:22.000Z thumbnail image
  8. Check
    47 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:40:45.000Z thumbnail image

Stay in the know with updates to Autologous TILs in Metastatic TNBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Autologous TILs in Metastatic TNBC Clinical Trial page.